Kornimate/medical-research-clean huggingface dataset:
collagen-pvp vs hylan g-f 20 in the treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis; Gonarthrosis

Summary: articular cartilage degradation is the main characteristic of osteoarthritis (oa), involving enzymatic and inflammatory mechanisms that change it into a chronic disease. since articular cartilage shows limited regenerative ability, several intra-articular drugs have been developed in order to decrease inflammation and provide a better clinical outcome to the patient.

this study aims to compare effectiveness of the treatment with intra-articular administration of collagen-pvp versus hylan gf 20, using the international knee documentation committee (ikdc) score, 6 months after treatment. hypothesis to test is: if effectiveness of intra-articular collagen-pvp is not lower than hylan gf 20 treatment in knee osteoarthritis subjects, then, statistically significant difference would not exist in ikdc score mean increase among treatment groups, after six months.

Eligibility criteria:
inclusion criteria: * aged between 40 and 80 years old * osteoarthritis in the knee rated ii or iii (kellgren-lawrence grading scale). * pain intensity (mos pain severity scale) greater than 40. * subject able to understand, co-operative and reliable. * written informed consent. exclusion criteria: * acute arthritis in the knee. * ongoing anticoagulant therapy. * skin infection at the injection site. * systemic or intraarticular (target knee) corticosteroids in the past 3 months. * viscosupplementation (target knee) in the past year * arthroscopy/osteotomy/surgery in the past 5 months (target knee). * any surgery scheduled in the next 6 months * concomitant rheumatic disease (rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, fibromyalgia). * severe varus/valgus deformity (\>15°). * frontal deformity greater than 20 degrees * history of allergy or hypersensitivity to hyaluronic acid or avian proteins * history/present evidence of: metabolic joint diseases; crystal arthropaties; ochronosis; acromegaly; haemochromatosis; wilson's disease; primary osteochondromatosis; heritable disorders.

Keywords: osteoarthritis intraarticular injections viscosupplementations type i collagen patient outcome assessment patient reported outcome measures
a clinical study to evaluate the tolerability of a topical antibiotic and retinoid used in a combined regimen with a bpo wash

Conditions: Acne Vulgaris

Summary: the purpose of this study is to evaluate the tolerability of a combined regimen of a topical antibiotic and retinoid and a benzoyl peroxide wash.


Eligibility criteria:
inclusion criteria: * subjects with mild to moderate facial acne vulgaris, with no history of known or suspected hypersensitivity or previous allergic reaction to any of the ingredients of the study products (eg, topical antibiotics, retinoids or benzoyl peroxide), capable of understanding and willing to provide signed and dated written voluntary informed consent and able to complete the study and to comply with study instructions. * female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study. exclusion criteria: * use of topical antibiotics on the face within the past 2 weeks or use of systemic antibiotics within the past 4 weeks.

Keywords: acne vulgaris
long-term assesment of patients operated for hypospadias in their childhood : urinary, aesthetical, sexual and psycho-social consequences

Conditions: Hypospadias

Summary: the purpose of this study is to assess the long term urinary, sexual, cosmetic and psycho-social outcomes of adult patients operated for hypospadias during childhood


Eligibility criteria:
inclusion criteria: * patients operated for hypospadias during childhood (before the age of 15) at the university hospital of besançon (france) exclusion criteria: * patients with a non-operated hypospadias * opposition to participate * legal incapacity
latino teen depression treatment study

Conditions: Depression

Summary: despite experiencing higher rates of depressive symptoms (center for disease control and prevention, 2020) and similar rates of major depressive disorder (mdd; substance abuse and mental health services administration (samhsa), 2019), latino adolescents in the u.s. are significantly less likely than their non-latino white peers to receive treatment for mdd (samhsa, 2019). the purpose of this study is to identify a stakeholder-preferred implementation strategy that may improve psychotherapy attendance among latino adolescents. latino adolescent-parent dyads and healthcare providers will be recruited from healthcare settings and social media. focus groups will be conducted with healthcare providers (n=5), and individual interviews will be conducted with latino adolescents with a diagnosis of depression (n=15) and their parents (n=15).


Eligibility criteria:
inclusion criteria for teens: * male gender * aged 13-17 years * diagnosed with major depressive disorder or persistent depressive disorder * referred to psychotherapy and/or prescribed antidepressant medications for depression exclusion criteria for teens: * experiencing imminent thoughts of self-harm or suicide * experiencing acute psychological distress (e.g., uncontrolled crying) inclusion criteria for parents: * parent or legal guardian of teen * able to read and speak english or spanish exclusion criteria for parents: * unable to read/speak english or spanish inclusion criteria for healthcare providers: * self-identification as regularly providing clinical care to latino adolescents with depression * be in a role in which they can provide or refer patients to depression treatment exclusion criteria for healthcare providers * unable to provide or refer to depression treatment

Keywords: adolescent latino depression treatment
effects of bariatric surgery on different compositions of trunk fat and mechanisms

Conditions: Bariatric Surgery Candidate; Adiposity; Fat Redistribution

Summary: this is a prospective, single-center, observational study to explore effects of bariatric surgery on different compositions of trunk fat and mechanisms.

this is a prospective, single-center, observational study to explore effects of bariatric surgery on different compositions of trunk fat and mechanisms. the primary outcome is effects of bariatric surgery on different compositions of trunk fat evaluated with mri for patients pending bariatric surgery before and 3 months after surgery. the secondary outcome is the associations of trunk fat reduction with improvement in metabolism indicators. before patients are enrolled in this observational study, the researchers will do a detailed screening of the subjects based on the inclusion criteria and the exclusion criteria to determine if the patients are appropriate for the study. patients who meet the conditions of the study will be required to sign an informed consent form.

Eligibility criteria:
inclusion criteria: * bmi of \>27.5 kg/m2 with t2dm; * bmi of \>32.5 kg/m2 with or without metabolic syndrome; * age 18-65 years old; * t2dm duration \< 15 years. exclusion criteria: * previous history of pancreatitis or pancreatic surgery; * serious t2dm complications or organic diseases; * alcohol addiction; * uncontrolled mental illness.
effects of pep on ic during it in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study will investigate the effects of positive expiratory pressure (pep) on hyperinflation in patients with chronic obstructive pulmonary disease (copd). inspiratory capacity (ic) is the primary outcome

this is a cross-over intervention assessing the effect of pep on ic and dyspnea in patients with copd performing an interval training (it) session. ic will be measured before, during and immediately after the it session. each participant will receive perform it sessions including either the use of a pep of 10 cmh2o or a pep of 1 cmh2o. the effects on ic and dyspnea on both pep levels will be assessed.

Eligibility criteria:
inclusion criteria: * stable copd since 1 month at least * able to understand the instructions exclusion criteria: * copd with a forced expiratory volume at one second \> 80% of predicted values * in exacerbation * orthopedic of neurological condition likely to interfere with the experimentation * contraindication to perform exercise
a clinical standardization study of the preferred acupuncture treatment protocol to treat functional constipation

Conditions: Constipation

Summary: the purpose of this study is to re-evaluate the therapeutic superiority and safety of acupuncture treatment using high quality and large sampled clinical research. the investigators want to provide a preferred treatment protocol, which is effective, safe, and easy to use in clinical practice. this research also clarifies that the insertion depth is a key factor in the therapeutic effect of acupuncture. the results of the study will help promote the development of the standardization of acupuncture.

functional constipation is a high morbidity disease. the life-long treatment of functional constipation can seriously impact a patient's quality of life. at present, one of the most frequently used treatment is catharsis, which deals with the symptom. there are three main problems with catharsis. first, there are no long-lasting effects once the patient stops taking medication. second, there are many side effects, including abdominal pain with defecation and diarrhea. third, long-term use of irritant laxatives will not only make the constipation become refractory and complex; but also, this type of medicine can harm the enteric nervous system, cause melanosis coli, or even carcinoma of colon. therefore, a therapy that is safe with minimal side effects and good short-term and long-term effects is urgently needed in functional constipation treatment. clinical practice shows that acupuncture may meets this need to some extent. the acupuncture therapy is safe and effective and the therapeutic effects are still present several months after the treatment has been completed.

Eligibility criteria:
inclusion criteria: * meeting the diagnosis of rome iii criteria; * aged from 18 to 75 years old; * no use of medicine for constipation about 2 weeks before the enrollment, no acupuncture treatment for constipation in the previous 3 months, and never joined any other trial in progress in the previous 3 months; * volunteered to join this trial and signed the informed consent form exclusion criteria: * irritable bowel syndrome, organic constipation or secondary constipation caused by endocrine, metabolic, nervous, postoperative diseases, or by drugs; * constipation with serious cardiovascular, hepatic or renal diseases, cognitive dysfunction, aphasia, mental disorders, or illness which affects the cooperation for examination and treatment; * women in gestation or lactation period; * abdominal aortic aneurysm or hepatosplenomegaly, etc.; * blood coagulation disorders or using anticoagulants regularly such as warfarin and heparin; * cardiac pacemaker carrier.

Keywords: acupuncture functional constipation
donor after circulatory death heart cap trial

Conditions: Heart Transplant

Summary: the portable organ care system (ocs™) heart for resuscitating, preserving and assessing hearts donated after circulatory death continued access protocol (ocs dcd heart cap)

to enable continued clinical access to dcd heart transplantation in the u.s. and to continue to collect additional data on the performance of the ocs heart system to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.

Eligibility criteria:
recipient inclusion criteria: * • primary heart transplant candidates * age ≥ 18 years old * signed: (1) written informed consent document; (2) authorization to use and disclose protected health information; and (3) consent to transmedics' use of recipients' unos/optn data and recipients' intermacs data. recipient exclusion criteria: * prior solid organ or bone marrow transplant * chronic use of hemodialysis or diagnosis of chronic renal insufficiency * multi-organ transplant.
the flocked swab and the traditional fiber swab for the diagnosis of the herpes simplex epithelial keratitis

Conditions: Herpes Simplex Keratitis

Summary: the purpose of this study is to compare a corneal sampling realized by a flocked swab (flocked swab regular 519cs01) with a sampling by traditional fiber swab (copan regular swab 164ks01 in polyester). their impact on the sensibility of the viral culture in the herpes simplex epithelial keratitis will be the primary objective of this study.

in our center, the flocked swabs became an important tool in the corneal sampling for viral keratitis, replacing rightly or wrongly the former traditional fibers swab. no research was specifically designed to study the corneal taking with these swabs. nevertheless, numerous reasons would motivate it, because of the peculiarities in ophthalmology: the corneal sampling has to be made with the slit lamp rather than in a macroscopic manner; the corneal lesion are often millimetre-length and confined; the histology of the cornea is unique and compares only imperfectly with other structures of the human body like the nasal mucosa. in these circumstances, the properties of the stalk (rigidity, length) and of its extremity (roughness, textures, absorbance) can influence the quality of the sampling and the final result of the culture.

Eligibility criteria:
inclusion criteria: * slit lamp signs at the initial examination that are compatible with an herpes simplex epithelial keratitis (herpes simplex dendrite, herpes simplex geographic ulcer) exclusion criteria: * topical or systemic antiviral therapy during the last 14 days patient with herpes simplex stromal keratitis without epithelial involvement herpetic lesion outside the cornea

Keywords: flocked swab traditional fiber swab herpes simplex epithelial keratitis quantitative pcr
risperidone in the treatment of ptsd in women survivors of domestic abuse and rape trauma

Conditions: Post-Traumatic Stress Disorder

Summary: this medical study is an assessment of clinical response in women with posttraumatic stress disorder (ptsd) due to domestic violence or rape trauma when treated with risperidone. response to risperidone or placebo (inactive drug) is measured by clinician administered ptsd scale (caps) and treatment outcomes ptsd scale (top-8). second, the effect of risperidone on depressive and anxiety symptoms will be assessed using the hamilton rating scale for anxiety, hamilton rating scale for depression and the clinical global impression.

risperidone is an atypical antipsychotic that has been shown to be effective in both the core ptsd symptoms and psychotic symptoms associated with combat-induced ptsd in males. case series have shown that risperidone is possibly effective in monotherapy or adjunctively in treating ptsd patients. however, risperidone has never been tested in women with severe ptsd. thus, we propose extending and expanding this research to another antipsychotic, risperidone, in a cohort of women who suffer ptsd as a consequence of domestic violence and/or rape trauma.

Eligibility criteria:
inclusion criteria: * women with dsm-iv clinical diagnosis of ptsd caused by domestic violence or rape, who are able to attend weekly clinic appointments; * age 19 -64, not pregnant and either sterile or using acceptable contraception; * a willingness and ability to provide competent signed informed consent; * a level of understanding sufficient to perform all tests and examinations required by the protocol (including fluency of spoken english). exclusion criteria: * any diagnosis of schizophrenia or bipolar i disorder; or active substance dependence. * unstable general medical condition or serious illness (e.g., death or hospitalization is anticipated within one year), poor liver or kidney function-subjects with prior non-response to risperidone for the treatment of ptsd with an adequate trial * enrolment in any drug study within the last 60 days. * pregnancy or nursing. * any subject judged clinically to be at serious suicidal risk in the opinion of the investigator.
kerecis fish skin grafts with and without platelet rich plasma (prp)

Conditions: Non-healing Wound

Summary: this prospective, randomized pilot study compares the use of a xenograft with prp to a xenograft alone for chronic, nonhealing wounds.


Eligibility criteria:
inclusion criteria: * patient is over the age of 18 years; * the targeted wound is deemed a chronic, nonhealing wound after six weeks of treatment; - - patient of dr. eldridge, dr. glenn, or dr. worley; * target wound size must be between 2 cm x 2 cm x 0.1 cm deep and 10 cm x 10 cm x 5 cm deep; * surgical candidate for standard of care kerecis® xenograft surgery. exclusion criteria: * patient with hemoglobin values less than 6.9 g/dl drawn at least 30 days prior to the kerecis® xenograft surgery; * patient with a known allergy or other sensitivity to fish material; * patient is currently undergoing chemotherapy or radiation therapy; * the targeted wound is of autoimmune origin; and non-english-speaking patients.

Keywords: xenograft prp platelet rich plasma
real-world effectiveness of bevacizumab based on aurelia in platinum-resistant recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: this study will evaluate the efficacy and safety profile, response rate, progression free survival, overall survival of bevacizumab (avastin) added to chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma with disease progression within 6 months of platinum treatment.


Eligibility criteria:
inclusion criteria: 1. patients who have histologically or cytologically confirmed recurrent epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer. 2. patients who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen) 3. patients who have underwent chemotherapy of either weekly paclitaxel + bevacizumab, topotecan + bevacizumab, pegylated liposomal doxorubicin + bevacizumab in 2nd line or 3rd line chemotherapy. exclusion criteria: 1. patients with previous treatment with bevacizumab. 2. patients who received bevacizumab combination therapy in 4th line or more chemotherapy.
lvrs versus blvr in patients with homogenous emphysema, club-he trial

Conditions: Emphysema or COPD

Summary: this is a prospective randomized clinical trial comparing surgical and bronchoscopic lung volume reduction in patients with advanced homogeneous emphysema suitable for both procedures.

lung volume reduction surgery (lvrs) as well as bronchoscopic lung volume reduction (blvr) provide functional improvements in selected patients with homogenous emphysema and pronounced hyperinflation. a direct comparison of lvrs and blvr in patients with homogenous emphysema is not available, thus the study will provide important data to guide treatment selection in this patient population.

Eligibility criteria:
inclusion criteria: * copd iii-iv * age ≥ 18 years * fev1 \< 50% predicted after bronchodilatation * significant hyperinflation (tlc \>100% predicted, rv \> 200% predicted, rv/tlc \> 60%) * non-smoker or ex-smoker for \> 3 months (documented by cotinine testing) * 6 mwt \>150 m and ≤ 450m * mrc dyspnea score \> 3 * homogenous emphysema as assessed by hr-ct (\< 15% difference in emphysema destruction score between target lobe and ipsilateral lobe) \[16, 17\] * uni- or bilateral collateral ventilation (cv) negative result assessed fissure completeness\>95% in qct and confirmed by a bronchoscopic procedure (chartis©) * optimal medical therapy for \> 3months, sufficient rehabilitation status with no need for further training/rehabilitation or rehabilitation within 6 months prior to intervention. * body mass index (bmi) \> 18, but \< 35 kg/m2 * daily dose of prednisone ≤ 10mg exclusion criteria: * contraindication against either lvrs or blvr and/or to surgery and bronchoscopy in general * major comorbidities limiting survival * age ≥ 80 years * nicotine abuse within 3 months (documented by cotinine testing) * predominance of either left or right lung of \>70% in perfusion spect scintigraphy * fev1 and/or dlco \<20% predicted (post bronchodilatation) * untreated hypoxemia (pao2 \< 50 mmhg) * untreated hypercapnia (paco2 \> 50 mmhg) * significant pulmonary fibrosis or bronchiectasis * destroyed/vanished lung on hr-ct * previous chest surgery or bronchoscopic interventions * pulmonary hypertension (spap \> 35 mmhg) * active waiting list for lung transplantation * patient is not able to understand and willing to sign a written informed consent document. * pregnancy
obesity: cesarean health by incision placement

Conditions: Maternal Morbidity

Summary: hypothesis: a pfannenstiel cesarean skin incision placed under the pannus (should a pannus exist) will have a higher maternal morbidity composite rate than a cohen cesarean skin incision placed above the pannus (should a pannus exist).

introduction: obesity affects approximately 1/3rd of all reproductive-aged women and is associated with increased maternal morbidity during and after cesarean section. the optimal surgical approach has not been well elucidated for obese individuals. materials and methods: this is a randomized controlled trial comparing a pfannenstiel incision placed below the pannus (should a pannus exist) with a cohen incision placed above the pannus (should a pannus exist); allocation is 1:1 with stratification for pre-gestational diabetes and presence of pannus. the study will be assessed by intention-to-treat analysis looking composite maternal morbidity (wound complications within 6 weeks, endometritis, postpartum hemorrhage) as the primary outcome with secondary outcomes including wound complications, operative time, estimated blood loss, pain management, and patient and surgeon satisfaction. significant confounders will be assessed and adjusted in the multiple regression analysis accordingly. results: the investigators propose the cohen cesarean incision will result in statistically less maternal morbidity from cesarean section than the pfannenstiel incision. comment: the benefits of a cohen incision have been encouraged in non-obese pregnant women; the investigators propose that they be considered in obese women as well.

Eligibility criteria:
inclusion criteria: * bmi \> or = 35 kg/m2 at time of presentation for delivery * speaks english exclusion criteria: * bmi \< 35 kg/m2 at time of presentation or delivery * unable to consent (including language spoken other than english) * prior abdominal incisions or obstetric factors necessitating placement of incision in specified location, at the discretion of the attending surgeon * infection present (ie cellulitis) precluding incision placement at one of the randomization sites